Haleos Labs Limited
NSE: HALEOSLABS BSE: 540679
₹1286.50
(-0.09%)
Mon, 06 Apr 2026, 08:08 pm
Market Cap3.93B
PE Ratio19.60
Dividend0.12
Health Technology
Biotechnology
24.5KHaleos Labs Limited Analysis
dividend
- Dividends paid are thoroughly covered by earnings (28x coverage).
- SMS Lifesciences India only just started paying a dividend, it is too early to tell if payments are increasing.
- It is too early to tell whether SMS Lifesciences India has stable dividend payments.
- SMS Lifesciences India's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
- SMS Lifesciences India's dividend is below the markets top 25% of dividend payers in India (3.08%).
health
- SMS Lifesciences India is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- SMS Lifesciences India is profitable, therefore cash runway is not a concern.
- SMS Lifesciences India is profitable, therefore cash runway is not a concern.
- Debt is covered by short term assets, assets are 3x debt.
- SMS Lifesciences India's cash and other short term assets cover its long term commitments.
- Interest payments on debt are well covered by earnings (EBIT is 4x coverage).
- SMS Lifesciences India's level of debt (42%) compared to net worth is high (greater than 40%).
- High level of physical assets or inventory.
management
- The tenure for the SMS Lifesciences India board of directors is about average.
- The tenure for the SMS Lifesciences India management team is about average.
misc
- SMS Lifesciences India is not covered by any analysts.
- SMS Lifesciences India has significant price volatility in the past 3 months.
past
- SMS Lifesciences India has delivered over 20% year on year earnings growth in the past 5 years.
- SMS Lifesciences India's 1-year earnings growth is negative, it can't be compared to the 5-year average.
- SMS Lifesciences India used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- SMS Lifesciences India has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- SMS Lifesciences India's 1-year earnings growth is negative, it can't be compared to the IN Pharmaceuticals industry average.
value
- SMS Lifesciences India is good value based on assets compared to the IN Pharmaceuticals industry average.
- SMS Lifesciences India is good value based on earnings compared to the IN Pharmaceuticals industry average.
- SMS Lifesciences India is good value based on earnings compared to the India market.
- NSEI:SMSLIFE is up 25.7% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- NSEI:SMSLIFE is up 25.7% outperforming the market in India which returned 8% over the past month.
- SMS Lifesciences India's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- SMS Lifesciences India's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- SMSLIFE underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- SMSLIFE underperformed the Market in India which returned -14.5% over the past year.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800